GlassScriptPhysician profile
Devin G Mcadams
NPI 1184683864
$3,080.42
in general payments reported to CMS, 2019-2025
29 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $194 · 2021: $509 · 2022: $515 · 2023: $377 · 2024: $597 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $657.55 | 2019-2023 | |
| Organon LLC | $654.16 | 2021-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $246.90 | 2022-2025 | Veozah, Myrbetriq |
| Minerva Surgical, INC | $228.11 | 2019-2025 | |
| Pfizer INC. | $127.53 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $124.67 | 2019-2021 | |
| Agile Therapeutics, INC. | $118.88 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $109.05 | 2019-2024 | |
| Hologic Sales and Service, LLC | $102.63 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Avion Pharmaceuticals | $80.16 | 2019-2020 | |
| Allergan, INC. | $72.63 | 2019-2020 | |
| Roche Diagnostics Corporation | $69.48 | 2019 | |
| Coopersurgical, INC. | $65.40 | 2019-2024 | Endosee |
| Amgen INC. | $57.31 | 2019-2021 | |
| Sage Therapeutics, LLC | $54.71 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $40.04 | 2020-2025 | Slynd |
| Millicent US INC | $39.27 | 2024 | Intrarosa, Femring |
| Mayne Pharma Commercial LLC | $33.56 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.26 | 2021 | |
| Therapeuticsmd, INC. | $24.71 | 2021 | |
| Sumitomo Pharma America, INC. | $23.49 | 2024 | Myfembree |
| Medtronic, INC. | $21.34 | 2025 | Interstim |
| Lupin INC. | $16.48 | 2019 | |
| Mission Pharmacal Company | $15.72 | 2020 | |
| Covidien LP | $15.71 | 2020 | |
| Meditrina | $13.60 | 2025 | |
| Scynexis, INC. | $12.62 | 2022 | |
| Daiichi Sankyo INC. | $12.31 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.